
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : INT301
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Intrommune Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Intrommune Therapeutics Strikes Deal with Circuit Clinical®
Details : Based on this deal, Circuit Clinical will oversee the early clinical development of Intrommune’s lead drug, INT301, including a Phase 1b study planned for Q4 2020 and Q1 2021.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
October 20, 2020
Lead Product(s) : INT301
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Intrommune Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
